Last $18.19 USD
Change Today +0.34 / 1.90%
Volume 13.5K
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

zafgen inc (ZFGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/14 - $21.01
52 Week Low
07/18/14 - $17.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZAFGEN INC (ZFGN)

Related News

No related news articles were found.

zafgen inc (ZFGN) Related Businessweek News

No Related Businessweek News Found

zafgen inc (ZFGN) Details

Zafgen, Inc., a biopharmaceutical company, focuses on the provision of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical trials reduces the severity of nonalcoholic steatohepatitis and plasma glucose. Zafgen, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

10 Employees
Last Reported Date: 06/19/14
Founded in 2005

zafgen inc (ZFGN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $520.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $297.9K
Chief Medical Officer
Total Annual Compensation: $407.0K
Compensation as of Fiscal Year 2013.

zafgen inc (ZFGN) Key Developments

Zafgen Appoints Patrick Loustau as President

Zafgen, Inc. announced the appointment of Patrick Loustau to the position of President. Mr. Loustau has broad experience in creating and implementing differentiated global and market strategies, from clinical development through life cycle management and business development.

Zafgen, Inc. Appoints Frank E. Thomas to Serve on Audit Committee of Board of Directors as Chairman

Zafgen, Inc. announced that Frank E. Thomas, was elected to the board of directors of the company. Mr. Thomas was also designated to serve on the audit committee of the board of directors as chairman. As a non-employee director, Mr. Thomas will receive compensation in the same manner as the company's other non-employee directors. The company previously disclosed the terms of non-employee director compensation in the registration statement. Mr. Thomas has served as executive vice president and chief operating officer of AMAG Pharmaceuticals, Inc. since November 2011.

Zafgen, Inc.(NasdaqGS:ZFGN) added to NASDAQ Composite Index

Zafgen, Inc. will be added to the NASDAQ Composite Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZFGN:US $18.19 USD +0.34

ZFGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZFGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation ZFGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZAFGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at